Pharmacopsychiatry 2000; 33(2): 78-80
DOI: 10.1055/s-2000-7974
Case Report
Georg Thieme Verlag Stuttgart ·New York

Healthy Outcome under Olanzapine Treatment in a Pregnant Woman

J. Stingl1 , A. Berghöfer2 , D. Bolk-Weischedel2
  • 1Institute for Clinical Pharmacology, Charité, Humboldt University Berlin, Germany
  • 2Department of Psychiatry Freie Universität Berlin, Germany
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2000 (online)

Preview

Our report focuses on the case of a pregnant women with recurrent, paranoid schizophrenia. The patient was treated with Olanzapine from the 18th gestational week until delivery and during breast-feeding. No adverse events occurred during pregnancy, and the outcome was healthy. After delivery, the plasma level of olanzapine in the infant was one-third of the maternal plasma level, and during breast-feeding, it decreased to an undetectable limit.

References

MD Julia Kirchheiner,

Institut für Klinische Pharmakologie Universitätsklinikum Charité Humboldt-Universität zu Berlin

Schumannstraße 20-21

D-10098 Berlin

Germany